Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

Medidata sees revenue growth in Q2 as new clients spike

Medidata's customer base grew to 437 companies, with 30 new clients added in Q2 of 2014

Cloud-based solutions provider Medidata saw its revenue increase 22% over Q2 last year to $83.2m as the company’s customer base saw steep growth.

Related news

News in brief

McKesson Corporation, a healthcare services and information technology company, today announced a three-year extension to its pharmaceutical distribution agreement with CVS Caremark.

Zhejiang Jiuzhou Pharmaceutical has received an FDA warning letter after shipping a misbranded active pharmaceutical ingredient to the US.

Packaging Coordinators Inc (PCI) has announced its acquisition of Welsh contract development and manufacturing organisation (CDMO) Penn Pharmaceutical Services in a £127m ($215m) deal.

Increased emphasis on global clinical trials is promoting consolidation of contract research organisations (CROs), according to an industry report by M&A services firm 11T Partners.

Global Industry News

Amgen to slash 23% of its manufacturing footprint and 2,900 US jobs from in-PharmaTechnologist.com

Amgen is slashing 15% of its workforce and closing two US manufacturing facilities as part of a restructure the firm says will save $700m (€520m) a year.

Impax preparing response to FDA Form 483 with 10 observations from in-PharmaTechnologist.com

Impax Laboratories said it is working to address issues raised in an FDA Form 483 for its Taiwanese manufacturing facility, which was cited with 10 observations following an inspection in late July.

As Ebola virus rages, funding is the main constraint for new treatments, scientist says from BioPharma-Reporter.com

The worst Ebola virus outbreak in history continues to spread in West Africa as biopharma companies are hampered by funding issues in trying to bring treatments and vaccines to human trials, a scientist says.

Pfizer buys Baxter's vaccine business plus Austrian plant for $635m from BioPharma-Reporter.com

Pfizer has agreed to pay $635m (€474m) to Baxter International for its vaccine business, including two marketed products and a facility in Austria.

Where are tomorrow’s biosimilar hotspots? from BioPharma-Reporter.com

As the US FDA (Food and Drug Administration)’s biosimilars pathway is tested for the first time following Sandoz’s filgrastim submission last week, an expert predicts imminent biosimilars submissions from Celltrion and Hospira.

Amgen makes room for biosimilars despite cutting manufacturing 23% from BioPharma-Reporter.com

Amgen says it will continue to invest in manufacturing technologies to support its biosimilar pipeline despite announcing a restructuring that will reduce its manufacturing footprint by 23%.

Spotlight

Petition calls on FDA to amend informed consent requirements

Petition calls on FDA to amend informed consent requirements

The Center for Responsible Science  has asked the US FDA to adopt informed consent rules which ensure that trial participants...

US FDA to set more specific GMP regulations for outsourcing facilities

US FDA to set more specific GMP regulations for outsourcing facilities

Until final regulations are finished, the US FDA has released draft guidance describing the agency’s expectations for...

Parexel taps Middle East, North Africa with Atlas acquisition

Parexel taps Middle East, North Africa with Atlas acquisition

CRO Parexel has shifted its attention overseas with the acquisition of Atlas Medical Services, a provider of...

Trial documents: only 13% of firms are fully paperless, says Veeva

Trial documents: only 13% of firms are fully paperless, says Veeva

Contract research organisations (CROs) have been slow to adopt next-generation means of recording study documents, with only...

Pfizer offers update on risk-sharing deals with Icon, Parexel
Dispatches from DIA

Pfizer offers update on risk-sharing deals with Icon, Parexel

Three years after Pfizer began strategic partnerships with CROs Icon and Parexel, and the companies are still...

Key Industry Events

 

Access all events listing

Our events, Events from partners...